The announcement directly impacts Phathom Pharmaceuticals by highlighting its financial stability and reducing concerns over immediate capital needs. This can be seen as a positive signal to investors, as it suggests the company is well-managed and has a clear path forward without the immediate need for dilutive capital raising measures. This could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.